Amol Akhade, Senior Consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on X:
“Matterhorn Trial positive for EFS. Press release.
It will be interesting to see how PCR Co-related with EFS Delta of EFS and added toxicity.
FLOT Plus Durvalumab can be potentially new SOC.
Looking forward to the data.”
